Aytu BioPharma, Inc. AYTU
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · aytubio.com
Aytu BioPharma, Inc. is a pharmaceutical company headquartered in Denver, Colorado, focused on commercializing prescription therapeutics for complex central nervous system (CNS) diseases. The company's portfolio targets major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD), including EXXUA™ (gepirone) extended-release tablets approved for MDD in adults. Formerly known as Aytu BioScience, Inc., the company changed its name in March 2021.
Key ratios
CashFromOperationsYoYGrowth TTM -0.89
FreeCashFlowOnSale TTM -0.01
FreeCashFlowOnSale 2025 -0.03
FreeCashFlowOnSale 2024 -0.03
FreeCashFlowOnSale 2023 -0.07
NetIncomeMargin TTM -0.39
NetIncomeMargin 2025 -0.2
NetIncomeMargin 2024 -0.24
NetIncomeMargin 2023 -0.23
ReturnOnAssets TTM -0
ReturnOnAssets 2025 0.01
ReturnOnAssets 2024 0
ReturnOnAssets 2023 -0.02
ReturnOnEquity TTM -1.09
ReturnOnEquity 2025 -0.61
ReturnOnEquity 2024 -0.37
ReturnOnEquity 2023 -0.18
TotalRevenueYoYGrowth TTM 0.02
TotalRevenueYoYGrowth 2025 0.02
TotalRevenueYoYGrowth 2024 -0.12
TotalRevenueYoYGrowth 2023 -0.24
Recent news
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
2026-06-01 · Newswire
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
2026-05-13 · Investing News Network